Scott N. Holden

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

Ian E. Krop, Muralidhar Beeram, Shanu Modi et al. · Journal of Clinical Oncology · 2010 · 590 citations

Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer

Adrian M. Jubb, Herbert I. Hurwitz, Wei Bai et al. · Journal of Clinical Oncology · 2005 · 389 citations · Full text

Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab

William L. Ince, Adrian M. Jubb, Scott N. Holden et al. · JNCI Journal of the National Cancer Institute · 2005 · 322 citations

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

Scott N. Holden, Sabine Eckhardt, R. Basser et al. · Annals of Oncology · 2005 · 306 citations · Full text

Medicine, Pharmacology, Pathology +6

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Sandhya Girish, Manish Gupta, Bei Wang et al. · Cancer Chemotherapy and Pharmacology · 2012 · 261 citations · Full text